A new World Health Organization update puts the scale of the Bundibugyo virus outbreak in the Democratic Republic of the Congo at 10,668 confirmed cases and 5,198 deaths as of 3 November, a crude case fatality ratio of 48.7%. The figures, published on 6 November, come as the outbreak remains active across much of the country and as researchers prepare to widen a clinical trial with two vaccines designed specifically for the virus. The recommendation is an important research step, not a declaration that either candidate is ready for public use.
A national emergency with transmission still active
The WHO’s 6 November Disease Outbreak News counted 10,668 confirmed Bundibugyo virus disease cases and 5,198 deaths in the DRC by 3 November. The crude case fatality ratio was 48.7%. Cases had been identified in 67 health zones across eight provinces, and 51 of those zones had reported active transmission during the preceding 21 days. The update described sustained, high-level transmission overall, even though some individual areas were seeing a slight decline.
The geographic pattern matters because the outbreak is not confined to one isolated cluster. It spans Ituri, North Kivu, Haut-Uélé, Tshopo and four other provinces, with the WHO identifying Beni, Bunia and Mandima among the areas reporting the highest recent case and death numbers. Sixteen affected health zones had not reported a new case in the previous 21 days, but the remaining 51 were still reporting transmission. A zone with no recent report is not automatically proof that the wider outbreak is over. Ituri remained the most extensively affected province, with 28 of its 36 health zones reporting cases during the outbreak.
Sources: Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo, Kenya and Nigeria
The burden is reaching people before treatment centres
One of the most consequential details in the WHO update concerns where people are dying. Of 512 deaths reported since 21 October, 335 occurred in communities and 177 in treatment centres. The agency said the high proportion of community deaths, particularly among young children, points to persistent problems with early case detection and timely access to appropriate care. The figures suggest that many patients are dying before they can reach the facilities where specialised treatment and infection-control measures are available.
That pattern makes the response more difficult than simply expanding hospital capacity. Detecting illness earlier depends on people recognising symptoms, being able to seek care safely and quickly, and trusting health workers who arrive in their communities. Contact tracing also becomes harder when cases are identified late or when families have already been exposed. WHO Director-General Tedros Adhanom Ghebreyesus said displacement, rainy weather, attacks on health care and difficulty reaching remote areas were complicating the response.
Sources: Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo, Kenya and Nigeria · WHO Director-General's opening remarks at the media briefing – 4 November 2026
Why the 48.7% figure needs context
The 48.7% figure is a crude case fatality ratio: the cumulative deaths reported by the cut-off date divided by the cumulative confirmed cases. It is a stark measure of the outbreak’s reported toll, but it is not a forecast of what will happen to every infected person, nor a final estimate of the virus’s biological lethality. The ratio can change as new cases are detected, outcomes are confirmed and surveillance records are reconciled. It should be read as a surveillance indicator tied to a specific reporting window, rather than as a fixed property of every case.
The date attached to each total is therefore essential. The UK Health Security Agency’s week 44 outbreak-monitoring report, updated on 5 November, covered the period only through 1 November; it is an earlier snapshot, not a replacement for the WHO’s 3 November figures. WHO’s 4 November briefing had already described more than 10,000 cases and 5,000 deaths, while the later 6 November outbreak bulletin supplied the exact 3 November totals. This article uses that WHO snapshot consistently.
Sources: Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo, Kenya and Nigeria · Outbreaks under monitoring: week 44 (week ending 1 November 2026)
Tumaini is already testing an Ebola vaccine
The Tumaini platform trial began on 23 October, when its first participant was enrolled in Bunia, in Ituri province. It is a Phase 2/3 study designed to evaluate multiple vaccine candidates against Bundibugyo virus within one research framework. The trial uses ring vaccination: people who have had contact with a confirmed case are enrolled in vaccination groups so researchers can assess whether a candidate prevents disease among people at elevated risk of exposure. As a platform study, Tumaini is intended to compare candidates within a common trial structure rather than launch separate, unrelated studies.
The first candidate being evaluated is Ervebo, the vaccine licensed against disease caused by Zaire ebolavirus. That distinction is critical. Bundibugyo virus is a different species, and WHO says there is no licensed vaccine specifically for Bundibugyo virus disease. Evidence from animal studies suggests Ervebo might offer some protection, but WHO says there is not enough human evidence to establish whether it works against Bundibugyo; its use for this outbreak should therefore remain within a research protocol.
Sources: Two new candidate vaccines to join Ebola trial as treatment research advances · Ebola vaccines · First participant vaccinated in pivotal Phase 2/3 Bundibugyo vaccine trial in DRC
Two candidates receive a recommendation, not approval
The WHO Technical Advisory Group on Candidate Vaccine Prioritization has unanimously recommended adding two Bundibugyo-specific candidates to Tumaini: ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. The recommendation followed review of available preclinical and early clinical evidence, including safety and immunogenicity information. WHO said the two candidates would enter the trial only after the required national approvals have been obtained. The advisory group reviewed evidence across vaccine safety, animal challenge studies, manufacturing readiness and the available early human data.
The recommendation is notable because it would bring vaccines designed for Bundibugyo virus into evaluation during an active outbreak for the first time. It does not mean either candidate has demonstrated that it prevents infection or severe disease. The WHO advisory report describes the evidence reviewed by experts, while the trial is the mechanism through which safety and protection must be assessed in people at risk. Until those results exist, both products remain investigational candidates rather than available vaccines.
Sources: Two new candidate vaccines to join Ebola trial as treatment research advances · Fourth, fifth, sixth and seventh meetings of the WHO Technical Advisory Group on candidate vaccine prioritization (TAG–CVP) for Bundibugyo virus disease outbreak response: Meeting report, 1 September, 19 October, 22 October and 2 November 2026
Research will take time; response measures cannot wait
Four vaccination rings were already in place when WHO published its 4 November news release, with several more being prepared. The agency expects results from the vaccine trial in early 2027. That timetable means the new candidates are unlikely to provide an immediate answer to the outbreak. Their value is prospective: if testing demonstrates safety and protection, they could add a tool for future response and for people exposed during this epidemic.
For now, WHO says vaccines cannot replace measures that can save lives immediately: early care, contact tracing, isolation, safe and dignified burials, and trusted engagement with communities. The 51 health zones still reporting transmission underline the scale of the work ahead. The next milestones are national authorisations for the two recommended candidates, their actual enrolment in Tumaini, and evidence from the trial. Until then, the confirmed 3 November figures remain the clearest WHO snapshot of the DRC outbreak used in this report.
Sources: WHO Director-General's opening remarks at the media briefing – 4 November 2026 · Two new candidate vaccines to join Ebola trial as treatment research advances
